Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Incidence, risk factors and clinical consequences of neutropenia following kidney transplantation: a retrospective study.
Zafrani L, Truffaut L, Kreis H, Etienne D, Rafat C, Lechaton S, Anglicheau D, Zuber J, Ciroldi M, Thervet E, Snanoudj R, Mamzer MF, Martinez F, Timsit MO, Bergougnoux L, Legendre C. Zafrani L, et al. Among authors: bergougnoux l. Am J Transplant. 2009 Aug;9(8):1816-25. doi: 10.1111/j.1600-6143.2009.02699.x. Epub 2009 Jun 16. Am J Transplant. 2009. PMID: 19538494 Free article.
CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A.
Abou-Ayache R, Büchler M, Lepogamp P, Westeel PF, Le Meur Y, Etienne I, Lobbedez T, Toupance O, Caillard S, Goujon JM, Bergougnoux L, Touchard G. Abou-Ayache R, et al. Among authors: bergougnoux l. Nephrol Dial Transplant. 2008 Jun;23(6):2024-32. doi: 10.1093/ndt/gfm873. Epub 2008 Jan 16. Nephrol Dial Transplant. 2008. PMID: 18199693 Clinical Trial.
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study.
Choquet S, Leblond V, Herbrecht R, Socié G, Stoppa AM, Vandenberghe P, Fischer A, Morschhauser F, Salles G, Feremans W, Vilmer E, Peraldi MN, Lang P, Lebranchu Y, Oksenhendler E, Garnier JL, Lamy T, Jaccard A, Ferrant A, Offner F, Hermine O, Moreau A, Fafi-Kremer S, Morand P, Chatenoud L, Berriot-Varoqueaux N, Bergougnoux L, Milpied N. Choquet S, et al. Among authors: bergougnoux l. Blood. 2006 Apr 15;107(8):3053-7. doi: 10.1182/blood-2005-01-0377. Epub 2005 Oct 27. Blood. 2006. PMID: 16254143 Free article. Clinical Trial.
Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study.
Extra JM, Antoine EC, Vincent-Salomon A, Delozier T, Kerbrat P, Bethune-Volters A, Guastalla JP, Spielmann M, Mauriac L, Misset JL, Serin D, Campone M, Hebert C, Remblier C, Bergougnoux L, Campana F, Namer M. Extra JM, et al. Among authors: bergougnoux l. Oncologist. 2010;15(8):799-809. doi: 10.1634/theoncologist.2009-0029. Epub 2010 Jul 29. Oncologist. 2010. PMID: 20671105 Free PMC article. Clinical Trial.
A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma.
Morschhauser F, Recher C, Milpied N, Gressin R, Salles G, Brice P, Vey N, Haioun C, Colombat P, Rossi JF, Deconinck E, Lazreg F, Bergougnoux L, Delsol G, Attal M. Morschhauser F, et al. Among authors: bergougnoux l. Ann Oncol. 2012 Oct;23(10):2687-2695. doi: 10.1093/annonc/mds202. Epub 2012 Jul 5. Ann Oncol. 2012. PMID: 22767588 Free article. Clinical Trial.
Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy.
Bidard FC, Mathiot C, Degeorges A, Etienne-Grimaldi MC, Delva R, Pivot X, Veyret C, Bergougnoux L, de Cremoux P, Milano G, Pierga JY. Bidard FC, et al. Among authors: bergougnoux l. Ann Oncol. 2010 Sep;21(9):1765-1771. doi: 10.1093/annonc/mdq052. Epub 2010 Mar 16. Ann Oncol. 2010. PMID: 20233745 Free article.
Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up.
Colombat P, Brousse N, Salles G, Morschhauser F, Brice P, Soubeyran P, Delwail V, Deconinck E, Haioun C, Foussard C, Sebban C, Tilly H, Thieblemont C, Bergougnoux L, Lazreg F, Solal-Celigny P. Colombat P, et al. Among authors: bergougnoux l. Ann Oncol. 2012 Sep;23(9):2380-2385. doi: 10.1093/annonc/mds177. Epub 2012 Jul 10. Ann Oncol. 2012. PMID: 22782332 Free article. Clinical Trial.
19 results